Drug intelligence / Profile preview

cyclosporine + micro-emulsion lipid layer artificial tears

Development stage
Unknown
Lead developer
Novaliq
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

This is a combination ophthalmic therapy consisting of cyclosporine, an immunomodulatory agent, and a micro-emulsion lipid layer artificial tear. Cyclosporine acts as a calcineurin inhibitor that suppresses T-cell activation and reduces ocular surface inflammation, thereby increasing tear production in patients with dry eye disease. The micro-emulsion lipid layer artificial tear is designed to supplement the natural tear film by restoring or mimicking its lipid component, improving ocular surface lubrication and reducing evaporation. When used together, the micro-emulsion formulation enhances patient tolerance to cyclosporine by alleviating discomfort associated with its instillation and may improve compliance in individuals at risk of failing or who have previously failed immunomodulatory therapy for dry eye disease[1][5]. This combination targets both the underlying inflammatory process (via cyclosporine) and the physical deficiency of the tear film (via artificial tears), providing synergistic relief for dry eye symptoms.

Brand names
RestasisRefresh Optive Advanced
Other names
Cyclosporine + PFAT RefreshCyclosporine + Refresh Optive Advanced
02

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on cyclosporine + micro-emulsion lipid layer artificial tears.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine + micro-emulsion lipid layer artificial tears.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call